Trial reportThe Journal of experimental medicine2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.Journal of the International AIDS Society · 2024Pooled it
- Brief Report: Rebound HIV Viremia With Meningoencephalitis After Antiretroviral Therapy Interruption After Allogeneic Bone Marrow Transplant.Journal of acquired immune deficiency syndromes (1999) · 2022Trial
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.Nature medicine · 2021Trial
- HIV-1 variants are archived throughout infection and persist in the reservoir.PLoS pathogens · 2020Trial
- Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir.The Journal of experimental medicine · 2019Trial
- Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.Journal of virology · 2019Trial
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV.Nature communications · 2026Article
- Challenges in the Vaccination of HIV-Infected Individuals.Vaccines · 2025Review
- Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.medRxiv : the preprint server for health sciences · 2025Article
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- A die is cast: autologous neutralizing antibody resistance shapes the HIV reservoir during uninterrupted ART.The Journal of clinical investigation · 2025Article
- Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV.PLoS computational biology · 2025Article
- Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.Journal of virology · 2025Review
- Predicting antiretroviral therapy adherence status of adult HIV-positive patients using machine-learning Northwest, Ethiopia, 2025.BMC medical informatics and decision making · 2025Article
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.AIDS research and therapy · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Yehuda Z CohenLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.ORCID 0000-0001-6987-1478
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.ORCID 0000-0003-2492-3961
Lisa KrassnigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.ORCID 0000-0002-8722-4618
John P BartonDepartment of Physics and Astronomy, University of California, Riverside, CA.ORCID 0000-0003-1467-421X
Leah BurkeDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY.
Joy PaiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Ching-Lan LuLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Pilar MendozaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Christopher SleckmanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Katrina MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Allison L ButlerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Juan P DizonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Shiraz A BelblidiaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Maggi Witmer-PackLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Roy M GulickDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA.ORCID 0000-0001-6444-3562
Mila JankovicLaboratory of Molecular Immunology, The Rockefeller University, New York, NY.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY mcaskey@rockefeller.edu.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY nussen@rockefeller.edu.ORCID 0000-0003-0592-8564
Rockefeller University · USCornell University · USBeth Israel Deaconess Medical Center · USHoward Hughes Medical Institute · USUniversity of California, Riverside · US
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vilma Gabbay · 2017 to 2026
$28.3MTransforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MT32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8MInstitutional Career Development CoreKL2TR001865 · NCATS · ROCKEFELLER UNIVERSITY · PI SCHLESINGER, SARAH JANE · 2016 to 2025
$8.7M3BNC117 mAb in HIV-infected subjects on combination ARTU01AI118536 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2015 to 2017
$3.0MHoward Hughes Medical InstituteNCATS NIH HHS KL2 TR001865NCATS NIH HHS UL1 TR000043NIAID NIH HHS P30 AI124414NIAID NIH HHS U01 AI118536NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620
Abstract
A clinical trial was performed to evaluate 3BNC117, a potent anti-HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q
Indexed as
HIV-1HIV InfectionsRecombination, GeneticViral LoadAdolescentAdultAgedAnti-Retroviral AgentsFemaleFollow-Up StudiesHIV AntibodiesHumansMaleMiddle AgedAnti-Retroviral AgentsHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.